Abstracts tagged "Animal models"

Abstract Number: 1893 • 2018 ACR/ARHP Annual Meeting
Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
Zev Sthoeger^1,2, Amir Sharabi³, Heidy zinger¹, ilan asher⁴ and edna mozes¹, ¹Department of Immunology, The Weizmann institute of Science, Rehovot, Israel, ²Department of Allergy and Clinical Immunology, Kaplan Medical Center,, Rehovot, Israel, ³Department of Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Department of Allergy and Clinical Immunology, Kaplan Medical Center, Rehovot, Israel
Background/Purpose: Indoleamine-2,3-dioxygenase (IDO) is a tryptophan catabolizing enzyme which plays a role in immune regulation and in the pathogenesis of autoimmune disorders. Increased IDO activity…
Abstract Number: 398 • 2017 ACR/ARHP Annual Meeting
An on-Demand Drug Delivery System for the Treatment of Inflammatory Arthritis
Jing Yan¹, Nitin Joshi², Seth Levy², Sachin Bhagchandani², Kai Slaughter², Nicholas Sherman¹, Julian Amirault², Xueyin He², Tan Shi Rui², Michael Valic², Praveen Vemula³, Oscar Miranda², Oren Levy², Antonios Aliprantis⁴, Joerg Ermann¹ and Jeffrey Karp², ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Institute for Stem Cell Biology and Regenerative Medicine (inStem), Bangalore, India, ⁴Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Many types of inflammatory arthritis (IA) are treated with systemic therapy. In situations where only one or a few joints are active, intra-articular drug…
Abstract Number: 1324 • 2017 ACR/ARHP Annual Meeting
Angiotensin II Type I Receptor Deficiency Exacerbates Erosive Bone Destruction of hTNF-Transgenic Arthritis Mice
Takafumi Mito¹, Tomoyuki Mukai¹, Shunichi Fujita¹, Shoko Kodama¹, Akiko Nagasu¹, Teruki Sone² and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Nuclear Medicine, Kawasaki Medical School, Kurashiki, Okayama, Japan
Background/Purpose: Angiotensin II (Ang II) is known to function on various organs including kidneys, adrenal glands as well as the nervous and cardiovascular systems through…
Abstract Number: 1929 • 2017 ACR/ARHP Annual Meeting
Sustained Efficacy of Intra-Articular SB-061, a Novel Matrix Regulator Inspired By Aggrecan, in a Rat Model of Osteoarthritis
Kate Stuart¹, Julia Chen¹, Sharmi Saha¹, Harsha Kabra¹, Athene Chan¹, Kamal Egodoge¹, Jennifer Oskins², Chaohua Lin², Morten Karsdal³, Mark Chambers² and John Paderi¹, ¹Symic Bio, Emeryville, CA, ²Lilly Research Laboratories, Indianapolis, IN, ³Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark
Background/Purpose: No therapy for osteoarthritis (OA) has yet to deliver both structural and symptomatic benefits. Symic is approaching this unmet clinical need with a novel…
Abstract Number: 399 • 2017 ACR/ARHP Annual Meeting
Therapeutic Effect of Rosiglitazone-Mediated Dendritic Cells in Established Arthritis in Mice
Jin Jung Choi¹, Sang-Yoon Jung², Kyung-Su Park³, Chong-Hyeon Yoon⁴ and Dae-Seog Lim⁵, ¹Rheumatology, CHA University Medical Center at Bundang, Sungnam, Korea, Republic of (South), ²Internal Medicine, Bundang CHA Medical Center, Seongnam, Korea, Republic of (South), ³Internal Medicine, St. Vincent's Hospital, The Catholic University of Korea, Suwon, Korea, Republic of (South), ⁴Rheumatology, The Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea, Republic of (South), ⁵Department of biotechnology, CHA University, Sungnam, Korea, Republic of (South)
Background/Purpose: Rosiglitazone is a selective ligand for peroxisome proliferator-activated receptor-gamma (PPAR-γ), which is expressed by antigen presenting cells (APCs) and plays a fundamental role in…
Abstract Number: 1325 • 2017 ACR/ARHP Annual Meeting
Immune Responses to Peptides Containing Homocitrulline or Citrulline in the DR4-Transgenic Mouse Model of Rheumatoid Arthritis
Patrick Lac¹, Sheri Saunders¹, Elena Tutunea-Fatan¹, Lillian Barra², David Bell³ and Ewa Cairns², ¹Microbiology and Immunology, The University of Western Ontario, London, ON, Canada, ²Medicine, Microbiology and Immunology, The University of Western Ontario, London, ON, Canada, ³Medicine, The University of Western Ontario, London, ON, Canada
Background/Purpose: Antibodies to proteins/peptides containing citrulline (commonly measured using cyclic citrullinated peptide, CCP2) are hallmarks of Rheumatoid Arthritis (RA). These antibodies are strongly associated with…
Abstract Number: 2056 • 2017 ACR/ARHP Annual Meeting
Performance and Validity of Musculoskeletal Ultrasound in the Assessment of Synovial Inflammation in Experimental Acute Gout
Raquel Largo¹, Juan Pablo Medina², Sandra Perez-Baos², Victor Najera-Aleson², Aranzazu Mediero², Gabriel Herrero-Beaumont¹ and Esperanza Naredo³, ¹Bone and Joint Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ²Joint and Bone Research Unit, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain, ³Rheumatology, Joint and Bone Research Unit, IIS-FJD, Hospital Universitario Fundación Jiménez Díaz., Madrid, Spain
Background/Purpose: Musculoskeletal ultrasound (MS-US) has not been validated as a reliable technique to evaluate joint inflammation in an acute gout rabbit model. Rabbit has been…
Abstract Number: 400 • 2017 ACR/ARHP Annual Meeting
Combination of the Collagen-Induced Arthritis and Organic Dust-Induced Airway Inflammation Models As a Model of Interstitial Lung Disease in Rheumatoid Arthritis
Katherine Janike¹, Jill Poole¹, Geoffrey M. Thiele², Michael J. Duryee³, Lynell W. Klassen⁴, Amy Nelson⁵, Kristi Warren⁶, Benjamin Swanson⁷ and Ted R. Mikuls⁸, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Int Med/Sec of Rheum/Immun, Univ of NE Medical Ctr, Omaha, NE, ³Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ⁵Department of Medicine, University of Nebrasa Medical Center, Omaha, NE, ⁶Department of Medicine, University of Nebraska Medical Center, Omaha, NE, ⁷Department of Pathology, University of Nebraska Medical Center, Omaha, NE, ⁸Internal Medicine, Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid Arthritis (RA) is characterized by extra-articular involvement including interstitial/inflammatory lung disease (ILD). Whereas the coexistence of RA and ILD is known, mechanisms…
Abstract Number: 1327 • 2017 ACR/ARHP Annual Meeting
Decreased Inflammatory Arthritis in Human Serum Paraoxonase 1 Transgenic Mice
Christina Charles-Schoeman¹, Ani Shahbazian², Jennifer Wang³, Victor Grijalva⁴ and Srinivasa T. Reddy⁴, ¹University of California, Los Angeles, Los Angeles, CA, ²Medicine-Rheumatology, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine-Cardiology, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Paraoxonase 1 (PON1) is an HDL-associated protein, which hydrolyzes biologically active oxidized phospholipids and prevents oxidation of lipids in LDL and HDL. Increased lipid…
Abstract Number: 2145 • 2017 ACR/ARHP Annual Meeting
Anti-CXCR3 Antibody Suppresses Inflammation in C Protein-Induced Myositis Model
Ji Yong Choi¹, Joo Youn Lee², Ji Soo Park³, Sehui Shon³, Kathleen Phillips⁴, Eun Young Lee¹, Eun Bong Lee¹ and Yeong Wook Song^3,5, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, Korea, Republic of (South), ²Department of Molecular medicine and biopharmaceutical science, Seoul National University, seoul, Korea, Republic of (South), ³Department of Molecular medicine and biopharmaceutical science, Seoul National University, Seoul, Korea, Republic of (South), ⁴Pfizer Inc. Cambridge, MA. USA, Cambridge, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South)
Background/Purpose: CXCR3 is a chemokine receptor that plays an important role in T cell chemotaxis in human autoimmune diseases. CXCR3, which is activated by ligand…
Abstract Number: 401 • 2017 ACR/ARHP Annual Meeting
Cigarette Smoking Dose-Dependently Facilitates the Onset of Arthritis and Aggravates Arthritis in Female Experimental Arthritis Mice
Ji-Won Kim¹, Jennifer Lee², Yeon-Sik Hong³, Sung-Hwan Park² and Ji Hyeon Ju², ¹Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South), ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of (South)
Background/Purpose: Smoking is an important epidemiological factor for development of rheumatoid arthritis (RA). However, the mechanism of proarthritic role of smoking is not well understood.…
Abstract Number: 1328 • 2017 ACR/ARHP Annual Meeting
A Dual ICOS/CD28 Antagonist ICOSL Variant Ig Domain (vIgDTM) Potently Suppresses Mouse Collagen-Induced Arthritis and Human Xenograft Graft Vs. Host Disease (GvHD)
Stacey Dillon¹, Katherine Lewis¹, Ryan Swanson², Lawrence Evans², Michael Kornacker³, Steve Levin², Martin Wolfson⁴, Erika Rickel², Susan Bort², Sherri Mudri¹, Aaron Moss¹, Michelle Seaberg¹, Janhavi Bhandari⁴, Sean MacNeil⁴, Joe Hoover⁴, Mark Rixon⁴ and Stanford Peng⁵, ¹Translational Sciences, Alpine Immune Sciences, Seattle, WA, ²Immunology, Alpine Immune Sciences, Seattle, WA, ³Protein Engineering, Alpine Immune Sciences, Seattle, WA, ⁴Protein Therapeutics, Alpine Immune Sciences, Seattle, WA, ⁵Clinical, R&D, Alpine Immune Sciences, Seattle, WA
Background/Purpose: Our proprietary variant Ig domain (vIgD) platform creates novel, therapeutically-applicable protein domains with tailored specificity and affinity. These vIgDs are created through directed…
Abstract Number: 2227 • 2017 ACR/ARHP Annual Meeting
S100A9 Induces a Pain Response during Experimentally Induced Acute Synovitis
Arjen B. Blom¹, Edwin J. W. Geven¹, Martijn H. van den Bosch¹, Esmeralda N. Blaney Davidson¹, Peter M. van der Kraan¹ and Peter L. van Lent², ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Radboud University Nijmegen Medical Center, Rheumatology, Nijmegen, Netherlands
Background/Purpose: Synovitis-associated pain is an important aspect of arthritis pathology. Several inflammatory mediators released by the synovium have been implicated in the regulation of pain,…
Abstract Number: 402 • 2017 ACR/ARHP Annual Meeting
Alteration of the Intestinal Microbiome in the Preclinical Phase of Experimental Arthritis and the Efficacy of Microbiota Modulation in Established Arthritis in Mice
Rebecca Rogier¹, Heather Evans-Marin², Julia Manasson³, Peter M. van der Kraan⁴, Wim B. van den Berg⁵, Marije I. Koenders⁴, Jose U. Scher⁶ and Shahla Abdollahi-Roodsaz^7,8, ¹Experimental Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ²Division of Rheumatology, New York University School of Medicine, New York, NY, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁵Rheumatology Research and Advanced Therapeutics, Radboud University Medical Center, Nijmegen, Netherlands, ⁶New York University School of Medicine, New York, NY, ⁷Department of Medicine, Division of Rheumatoogy, New York University School of Medicine, New York, NY, ⁸Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: The composition of intestinal microbiota is perturbed in patients with new-onset and chronic rheumatoid arthritis (RA). However, it is not known whether the changes…
Abstract Number: 1329 • 2017 ACR/ARHP Annual Meeting
A Quantitative Framework for Evaluating Drug Combination Treatment in Rat Collagen-Induced-Arthritis Model
Amy Meng¹, Julie Di Paolo², Shringi Sharma³ and Anita Mathias³, ¹Clinical Pharmacology, Gilead Sciences, Foster City, CA, ²Immunology and Inflammation Biology, Gilead Sciences, Foster City, CA, ³Gilead Sciences, Foster City, CA
Background/Purpose: Filgotinib (FIL), a JAK1 inhibitor, and GS-9876, a SYK inhibitor, are currently being evaluated as once-daily monotherapy in subjects with rheumatoid arthritis (RA). A…

« Previous Page
1
…
3
4
5
6
7
…
25
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].